Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exicure, Inc.
  6. Company
    XCUR   US30205M1018

EXICURE, INC.

(XCUR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing the key strengths of its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.

Number of employees : 47 people.
Sales per Business
20202021Delta
Immuno-Oncology Therapeutics16.61100%-0.48100%-
USD in Million
Sales per region
20202021Delta
United States16.61100%-0.48100%-
USD in Million
Managers
Name Title Age Since
Matthias G. Schroff, Dr. President, Chief Executive Officer & Director 53 2022
Elias D. Papadimas Chief Financial Officer & Secretary 45 2022
Sarah Longoria Chief Human Resources & Compliance Officer 39 2021
Rebecca J. Peterson Vice President & Head-Corporate Communications 44 -
Weston Daniel, Dr. Vice President-Translational Research - 2020
Diego J. Garzón, Dr. Vice President-Business Development - 2020
Members of the board
Name Title Age Since
Elizabeth A Garofalo, Dr. Chairman 63 2022
Jeffrey L. Cleland, Dr. Independent Director 56 2019
Bali Muralidhar, Dr. Independent Director 41 2019
James R. Sulat Independent Director 70 2021
Matthias G. Schroff, Dr. President, Chief Executive Officer & Director 53 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 122,792,877 105,660,857 86.0% 0 0.0% 86.0%
Shareholders
NameEquities%
Aurasense LLC 11,257,629 9.17%
Armistice Capital LLC 8,602,643 7.01%
Tybourne Capital Management (HK) Ltd. 7,325,000 5.97%
Abingworth LLP 6,977,000 5.68%
Gates frontier LLC 5,064,703 4.12%
Renaissance Technologies LLC 3,249,200 2.65%
Broadfin Capital LLC 2,707,851 2.21%
The Vanguard Group, Inc. 2,693,541 2.19%
Prosight Management LP 2,426,508 1.98%
David R. Walt 2,058,777 1.68%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exicure, Inc.
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
EXICURE, INC.-43.05%15
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601
GENMAB A/S-22.70%18 636
ARGENX SE-5.49%16 947
BEIGENE, LTD.-50.96%13 709
NEUROCRINE BIOSCIENCES, INC.-1.23%8 040
EXELIXIS, INC.9.85%6 429
LEGEND BIOTECH CORPORATION-15.55%6 070
SAREPTA THERAPEUTICS, INC.-26.74%5 772
INTRA-CELLULAR THERAPIES, INC.12.92%5 575
HALOZYME THERAPEUTICS, INC.0.52%5 569
BIOCON LIMITED-10.56%5 008
ASCENDIS PHARMA A/S-38.21%4 638
MARAVAI LIFESCIENCES HOLDINGS, INC.-19.95%4 412
PHARMAESSENTIA CORPORATION29.86%3 685
ULTRAGENYX PHARMACEUTICAL INC.-38.79%3 599
CYTOKINETICS, INCORPORATED-7.83%3 598
Connections : Exicure, Inc.